DISCOUNT ZERTIFIKAT - VERTEX PHARMACEUTICALS | Market Closed - Börse Stuttgart 11:56:29 2024-06-03 am EDT | ||
| 226.4 EUR | -0.25% |
|
| Current month | -0.25% | ||
| 1 month | -0.39% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-03 | 226.4 | -0.25% |
| 24-05-31 | 226.9 | -0.01% |
| 24-05-30 | 227 | -0.27% |
| 24-05-29 | 227.6 | +0.59% |
| 24-05-28 | 226.2 | -0.14% |
Delayed Quote Börse Stuttgart
Last update June 03, 2024 at 11:56 am EDT
More quotesStatic data
| Product type | Discount Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Morgan Stanley |
| WKN | ME8J13 |
| ISIN | DE000ME8J138 |
| Date issued | 2024-02-09 |
| Maturity | 2024-12-20 (200 Days) |
| Parity | 1 : 1 |
| Emission price | 224.6 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 229 € |
|---|---|
| Lowest since issue | 221.4 € |
| Spread | 0.32 € |
| Spread % | 0.14% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
470.2
USD
Average target price
463.5
USD
Spread / Average Target
-1.41%
- Stock Market
- Certificates
- Certificat
